Janux Therapeutics (JANX) Shares Outstanding (2020 - 2026)
Janux Therapeutics (JANX) posted quarterly Shares Outstanding (Entity) of $60.9 million for Q1 2026, up 2.87% year-over-year from $59.2 million in Q1 2025, and up 0.8% quarter-over-quarter from $60.4 million in Q4 2025.
Janux Therapeutics (JANX) Shares Outstanding (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Shares Outstanding (Entity) for 7 consecutive years, with $60.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 2.87% year-over-year to $60.9 million; the TTM figure through Mar 2026 stood at $60.9 million (up 2.87% YoY), while the FY2025 annual figure was $60.4 million, up 2.23% from the prior year.
- Shares Outstanding (Entity) climbed to $60.9 million in Q1 2026 per JANX's latest filing, from $60.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $60.9 million in Q1 2026 and bottomed at $41.4 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $50.4 million across 5 years, with a median of $51.8 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 3273.63% — and 2023, when it increased 0.88%.
- Janux Therapeutics' Shares Outstanding (Entity) stood at $41.6 million in 2022, then increased by 11.14% to $46.3 million in 2023, then increased by 27.7% to $59.1 million in 2024, then grew by 2.23% to $60.4 million in 2025, then advanced by 0.8% to $60.9 million in 2026.
- Business Quant data shows JANX's Shares Outstanding (Entity) at $60.9 million in Q1 2026, $60.4 million in Q4 2025, and $60.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 62.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.94 Mn |
| Mar 31, 2026 | 62.67 Mn |
| Dec 31, 2025 | 61.97 Mn |
| Sep 30, 2025 | 62.02 Mn |
| Jun 30, 2025 | 61.90 Mn |
| Mar 31, 2025 | 61.79 Mn |
| Dec 31, 2024 | 53.75 Mn |
| Sep 30, 2024 | 54.63 Mn |
| Jun 30, 2024 | 54.45 Mn |
| Mar 31, 2024 | 49.05 Mn |
| Dec 31, 2023 | 44.02 Mn |
| Sep 30, 2023 | 45.71 Mn |
| Jun 30, 2023 | 41.84 Mn |
| Mar 31, 2023 | 41.76 Mn |
| Dec 31, 2022 | 41.47 Mn |
| Sep 30, 2022 | 41.53 Mn |
| Jun 30, 2022 | 41.45 Mn |
| Mar 31, 2022 | 41.32 Mn |
| Dec 31, 2021 | 23.53 Mn |
| Sep 30, 2021 | 41.13 Mn |